GBAF Logo
Global Banking & Finance Awards® 2026 Nominations open, free to enter Nominate now →
C

Clover Biopharmaceuticals 2197.HK · HKD

Health Care · HKEX · 🇭🇰 Hong Kong

Compare

1.42

+5.19%

Close of 9 Nov 2026, in HKD

Search any instrument

Reference data, closing prices and charts across 45,000 companies, plus crypto, commodities and currencies.

About Clover Biopharmaceuticals

Its shares trade on HKEX under the ticker 2197.HK. It has been listed since 5 November 2021. In the fiscal year to 31 December 2025, it reported revenue of CN¥4.0m and a net loss of CN¥232.7m. At that date it held total assets of CN¥533.5m and shareholders' equity of −CN¥2.09bn.

Clover Biopharmaceuticals Ltd. engages in the research and development of biopharmaceutical products. The company is headquartered in Shanghai, Shanghai. The company went IPO on 2021-11-05. The firm's main business is the development of new vaccines and biotherapeutic candidates for infectious diseases, cancer and autoimmune diseases. The firm's products are mainly used to treat the new coronavirus, malignant ascites, and ankylosing spondylitis.

Figures and description from our data supplier, not checked against the company's own report.

Company facts

Sector
Health Care
Industry
Biotechnology
Listed since
5 Nov 2021
Employees
764

Leadership

Pay as last reported

  • Dr. Peng LiangExecutive Chairman of the BoardCN¥7.4m
  • Mr. Joshua G. LiangChief Executive Officer, Executive DirectorCN¥14.7m
  • Mr. Phillip Eric LeeChief Financial Officer, Chief Operating Officer
  • Dr. Nicholas JacksonPresident - Global Research and Development
  • Dr. Xiaobing LiExecutive Vice President, Head - Product Development, Program and Portfolio Management
  • Dr. Michael BerryChief Technical Operations Officer
  • Dr. Philippe BishopChief Medical Officer - Oncology
  • Ms. Htay Htay HanChief Medical Officer - Vaccine
  • Ms. Hing Ling ChauJoint Company Secretary
  • Ms. Xiaoyan WangJoint Company Secretary
  • Dr. Donna AmbrosinoNon-Executive Director
  • Dr. Ralf ClemensNon-Executive Director

Environmental, social and governance

Scores out of 100, from our data supplier

ESG
Overall
0
Environment
0
Social
0
Governance
0

SWOT analysis

AI-generated by our data supplier. Not written or checked by our editors.

AI-generated

Strengths

  • Developing new vaccines and biotherapeutic candidates for infectious diseases, cancer, and autoimmune diseases.
  • Main products treat new coronavirus, malignant ascites, and ankylosing spondylitis.
  • 764 full-time employees support research and development efforts.

Weaknesses

  • IPO on 5 November 2021 limits long-term financial stability.
  • Headquartered in Shanghai, China, which may affect global market access.
  • Limited product portfolio compared to larger biotech firms.

Opportunities

  • Growing demand for biopharmaceuticals in the Health Care sector.
  • Expansion into new markets for treating infectious diseases and cancer.
  • Increased investment in biotechnology research and development.

Threats

  • Intense competition in the biotechnology industry.
  • Regulatory challenges for new vaccine approvals.
  • Economic downturns affecting healthcare spending.

Sources and methodology

Data on this tab
Our data supplier
Chart on the Overview
TradingView

Nothing here is investment advice. Prices can be delayed or wrong, so check with the exchange before relying on them. Data for this page. How we cover markets.